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Abstract
Over the past decade there has been a significant shift to the use of murine models for
investigations into the molecular basis of respiratory diseases, including asthma and chronic
obstructive pulmonary disease. These models offer the exciting prospect of dissecting the
complex interaction between cytokines, chemokines and growth related peptides in disease
pathogenesis. Furthermore, the receptors and the intracellular signalling pathways that are
subsequently activated are amenable for study because of the availability of monoclonal
antibodies and techniques for targeted gene disruption and gene incorporation for individual
mediators, receptors and proteins. However, it is clear that extrapolation from these models
to the human condition is not straightforward, as reflected by some recent clinical
disappointments. This is not necessarily a problem with the use of mice itself, but results
from our continued ignorance of the disease process and how to improve the modelling of
complex interactions between different inflammatory mediators that underlie clinical
pathology. This review highlights some of the strengths and weaknesses of murine models
of respiratory disease.
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Introduction
The incidence of respiratory diseases such as asthma and
chronic obstructive pulmonary disease (COPD) continue
to increase despite the availability of current methods of
treatment and there is therefore a need to improve our
understanding of the pathophysiology of these diseases to
permit the development of novel therapeutic agents.
Although the exact causes of asthma and COPD are not
completely understood, it is clear that both diseases are
characterized by inflammation of the airways and a decline
in respiratory function. In asthma, several inflammatory cell
types are thought to contribute toward the pathogenesis
of this disease, including eosinophils [1•] and CD4+ T lym-
phocytes [2•], whereas it is thought that CD8+ lympho-
cytes [3•] and neutrophils [4•] are important in COPD.
Another important feature of these diseases is the pres-
ence of airway wall remodelling. There is evidence of
hyperplasia/hypertrophy of airway smooth muscle,
increased collagen deposition beneath the basement
membrane, increased production of mucus, angiogenesis
and alterations in the extracellular matrix in asthma [5•]. In
COPD, there is evidence of mucous gland hyperplasia,
increased hypertrophy of bronchiolar smooth muscle,
fibrosis of the small airways and, in emphysema, destruc-
tion of alveolar tissue [6•]. On the basis of the findings
obtained from autopsy, the analysis of biological fluidshttp://respiratory-research.com/content/1/2/082
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and, more recently, biopsies from individuals with respira-
tory disease, a variety of animal models have been used to
study many of the characteristic features of these dis-
eases. For example, in asthma research, there are models
of airway inflammation that have been developed in sheep,
dogs, cats, rabbits, rats, guinea-pigs and primates. In
general, these models are useful; moreover, there are
known instances of natural sensitivity to environmental
allergens in sheep, dogs and primates. Furthermore, their
large size means that repeated measurements can be
made quite easily within the same animal.
The mainstay of treatment for asthma includes bron-
chodilators such as b2-adrenoceptor agonists and gluco-
corticosteroids; for COPD, ipratropium bromide and
b2-adrenoceptor agonists are used. With the aid of animal
models, a new class of anti-asthma drug (the leukotriene
antagonists) has been introduced clinically [7] and clinical
trials are in progress with another drug class, the phos-
phodiesterase 4 (PDE4) inhibitors [8]. Although the intro-
duction of one new drug after 30 years for the treatment of
asthma seems disappointing, it is worth remembering that
our understanding of the disease process has altered from
a simple model of controlling bronchoconstriction to
attempts at modulating the inflammatory response and the
remodelling of the structural airway. Furthermore, animal
models have been useful in the development of better
bronchodilator drugs such as long-acting b2-adrenoceptor
agonists, including salmeterol and formoterol, better glu-
cocorticosteroids (for example fluticasone) and in the
development of leukotriene antagonists. Despite the criti-
cisms and imperfections of animal models in general, they
still offer us a useful tool in the study of respiratory airway
disease.
Murine models of airway inflammation
The use of mice as models of human respiratory diseases
began to emerge in the early 1990s, and there were more
than 500 publications in the latter half of that decade. The
principal reason for using mice is that it enables investiga-
tors to study the role of the immune system in respiratory
disease. Indeed, considerable attention is now focused on
understanding the role of cytokines, chemokines and
growth related peptides in asthma because these sub-
stances are often detected in bronchial tissue and have a
wide variety of pharmacological and immunological activi-
ties [9•]. The mouse model is amenable for study because
of the existence of monoclonal antibodies specific for
murine proteins, and the availability of knockout and trans-
genic mice. It is these latter two aspects that make the use
of the mouse a powerful biological tool in the study of
inflammatory disease because this technology is not cur-
rently available in other species. Furthermore, the lack of
selective non-peptide antagonists to many of the cytokine,
chemokine and growth factor receptors makes these
models highly attractive.
As with other animal models, murine models of allergic
inflammation show many of the characteristic features of
the clinical disease. Thus, allergic mice undergo early and
late ‘asthmatic’ responses [10•] and demonstrate serum-
specific IgE, recruitment of lymphocytes, eosinophils and
bronchial hyper-responsiveness to human relevant anti-
gens such as Der p1 [11•]; murine models can also be
used to study various aspects of airway remodelling after
protocols involving chronic challenge with antigens [12].
Moreover, many of the cytokines, chemokines, growth
related peptides and their receptors that are expressed in
human respiratory disease are also found in these allergic
models of inflammation.
Another important aspect of any ‘asthma’ model is
whether some of the characteristic features of the disease
are attenuated by drug treatment. Thus, b2-adrenoceptor
agonists provide effective bronchoprotection against
antigen challenge, and glucocorticosteroids attenuate the
development of the late asthmatic response [10]. Simi-
larly, glucocorticosteroids are effective at inhibiting the
recruitment of eosinophils and bronchial hyper-responsive-
ness after chronic challenge with antigens [13]. There is
currently enormous interest in the possible anti-inflamma-
tory activity of PDE4 inhibitors for the treatment of asthma
and COPD [8] and it is of interest that the PDE4 inhibitor,
rolipram, attenuated eosinophilia and bronchial hyper-
responsiveness in a murine model of allergic inflammation
[14]. As with other models, murine models of respiratory
disease can be modulated by current therapeutic modali-
ties and therefore offer the possibility of testing potentially
novel anti-inflammatory agents. It is also clear that many
false positives will be found that will fail the clinical test
and will therefore require an adjustment to our current
concepts of disease pathophysiology. This iterative
process between biological modelling and clinical evalua-
tion is not unique to human respiratory disease but is also
a feature of other human diseases, including cardiovascu-
lar disease and cancer.
What we have learned from these models
It is immediately obvious that our understanding of the
role of the immune system in the initiation and propaga-
tion of the inflammatory response in the airways has
increased enormously. Furthermore, the complex path-
ways that are being realized have offered an array of
potential target sites for the development of novel thera-
peutic strategies for the control of inflammatory disease.
The current model of airway inflammation in the mouse is
one driven by T helper type 2 (Th2) lymphocytes sec-
ondary to antigen presentation from dendritic cells [2].
Antigen-specific Th2 cell clones generate a range of
cytokines, including interleukin (IL)-4, IL-5, IL-9 and IL-13,
which are important for the regulation of a range of inflam-
matory cells, including B cells, eosinophils, epithelial cells
and fibroblasts. Both IL-4 and IL-13 are important in theRespiratory Research    Vol 1 No 2 Vasquez and Spina
isotype switching of B cells to the IgE-secreting pheno-
type and have also been implicated in the recruitment of
eosinophils to the airways. Furthermore, cytokines such
as IL-4 and IL-9 can induce eosinophil recruitment by the
stimulation of chemokine production from airway epithe-
lium and fibroblasts, whereas IL-5 is an important
cytokine for the development, recruitment and mainte-
nance of eosinophils within the airways. Cytokines are
also implicated in airway remodelling associated with
asthma, because several studies have shown the ability of
IL-6, IL-9 and IL-11 to promote fibroblast proliferation and
subepithelial fibrosis. The interaction between the
immune system and resident cells such as the epithelium
and fibroblasts highlights multiple interactions and inter-
connected networks that are thought to be important in
the propagation of the inflammatory response and airway
wall remodelling [2,15,16].
However, it is also clear that these models have given us
conflicting information about the critical importance of
single proteins to the inflammatory response; this is more
a reflection of the exuberance of investigators in pursuing
the ‘holy grail’ of inflammation, namely a ‘single mediator’
hypothesis. As an example, the role of eosinophils in the
pathophysiology of asthma is central to our thinking on
this disease [1]; although there are numerous reports sup-
porting this view, this is not a universal finding [17••]. This
is a picture that is mirrored in murine models, in which
there are numerous reports supporting a role for IL-5 and
eosinophils in the ‘asthma’ response [10,18] but under dif-
ferent experimental conditions bronchial hyper-responsive-
ness is not dependent on the eosinophil [11,18]. It is clear
that the lack of a unified hypothesis for the role of various
inflammatory substances and cells in the allergic response
is a consequence of the sheer complexity of a process
that is not completely understood and is unlikely to be
described by a linear function but one that is highly
complex [19•,20•].
Another important characteristic feature of asthma is
bronchial hyper-responsiveness that is a major determi-
nant of the irritability of the airways to environmental
stimuli such as cold air, exercise, distilled water, pollutants
and allergens. It is clear that strategies designed to sup-
press bronchial hyper-responsiveness will have a benefi-
cial therapeutic outcome [21]; understanding the
mechanisms that lead to this phenomenon is therefore of
considerable importance. There are challenges to the
measurement of respiratory mechanics in the mouse, and
current methods are available that permit the determina-
tion of airway responsiveness to either serotonin or metha-
choline in this species [22]. The change in responsiveness
typically observed in such experiments is approx. 2–5-fold,
which is of a similar magnitude to that normally seen after
an exacerbation of asthma. Before antigen challenge the
baseline responsiveness to spasmogens is no different
from that in controls; in this respect, mice, like other animal
models, differ from humans; they are therefore models of
asthma exacerbation to allergens. However, there are
examples of mice with a genetic predisposition to
increased airway sensitivity to spasmogens in comparison
with other strains [22], or altered responsivity after the
incorporation of transgenes (such as IL-6, IL-9 and IL-11)
[15]. Superimposing the allergic response determined by
Th2 cells in these models could be used to study the inter-
action between allergic inflammation and structural cells in
the overall disease process [23].
Thus, it is clear from current models that specific cytokines
and chemokines can be targeted to modulate airway
inflammation. However, there are a number of conflicting
reports citing the importance of several of these cytokines
to this response. In some cases, gene knockout strategies
often reveal alternative pathways that are ‘recessive’ under
physiological conditions but become important when a
‘dominant’ pathway is removed. Alternatively, dependence
on a particular pathway might be under the control of
genetic differences between species, which begs the
question as to which model is a better approximation of
the clinical condition [18]. If we bear these caveats in
mind, important information on the roles of individual
cytokines and chemokines, or groups of these sub-
stances, in the inflammatory response can still be obtained
and novel anti-inflammatory drugs can be developed and
ultimately tested in the clinic, which is the key test of any
drug under investigation.
Potential novel therapeutic agents
Mice have long been the domain of immunologists and it is
only recently that pharmacologists have discovered the
possibilities that are being offered in understanding the
role of the immune system in the context of human airway
disease. The ultimate test of whether murine models can
teach us anything about respiratory disease will be in the
development of novel anti-inflammatory agents. Several
novel therapeutic agents have been tested in the clinic.
Thus, rhuMab 25, monoclonal antibody against human IgE
[24] and IL-4R [25] have had modest clinical effects,
whereas anti-IL5 antibody [26] and IL-12 [27] treatment
did not seem to modulate the late asthmatic response or
bronchial hyper-responsiveness. It is clear that these
studies rely on the ‘single mediator’ hypothesis, and
strategies designed to suppress inflammatory cell function
will prove more successful. To this end, drug companies
are attempting to define novel targets involved in the intra-
cellular signalling pathways used by cytokines and
chemokines that can be readily tested in murine models.
Moreover, strategies attempting to suppress Th2 lympho-
cyte function by upregulating Th1 lymphocyte activity, or
downregulating antigen presentation processes, offer an
exciting new area of research that can be readily tested in
murine models [28].http://respiratory-research.com/content/1/2/082
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Conclusion
Murine models of respiratory disease have taught us much
about the role of the immune system in these diseases
and the complexity of airway inflammation. We have gone
through the first phase of the use of these models, investi-
gating the effect of removing or adding single mediator
genes on the inflammatory response. It is the next step,
understanding the integration of different signals and their
pathways to the overall inflammatory response, that will
bring us closer to defining novel therapeutic pathways in
respiratory disease.
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